10:34 AM EDT, 10/22/2024 (MT Newswires) -- Akebia Therapeutics ( AKBA ) said Tuesday it signed a commercial contract with a kidney care services provider to help expand access to Vafseo, or vadadustat, for patients on dialysis.

Vafseo is indicated to treat anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, the company said.

Under the multiyear contract, physicians will be able to prescribe Vafseo to patients on dialysis as deemed clinically appropriate. Akebia said it expects Vafseo to be available in the US in January 2025.

The company's shares were up nearly 6% in recent trading.

Price: 1.45, Change: +0.08, Percent Change: +5.84